Stem definition | Drug id | CAS RN |
---|---|---|
antibiotics, cefalosporanic acid derivatives | 5352 | 1225208-94-5 |
None
Property | Value | Reference |
---|---|---|
S (Water solubility) | 100 mg/mL | Bocci G, Oprea TI, Benet LZ |
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Bocci G, Oprea TI, Benet LZ |
Date | Agency | Company | Orphan |
---|---|---|---|
April 23, 2020 | EMA | Shionogi B.V. | |
Nov. 14, 2019 | FDA | SHIONOGI INC |
None
None
None
None
Source | Code | Description |
---|---|---|
ATC | J01DI04 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Other cephalosporins and penems |
FDA CS | M0003827 | Cephalosporins |
FDA EPC | N0000175488 | Cephalosporin Antibacterial |
CHEBI has role | CHEBI:26672 | siderochromes |
CHEBI has role | CHEBI:36047 | antibacterial drugs |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Pyelonephritis | indication | 45816000 | DOID:11400 |
Urinary tract infectious disease | indication | 68566005 | |
Escherichia coli urinary tract infection | indication | 301011002 | |
Proteus urinary tract infection | indication | 301012009 | |
Pseudomonas urinary tract infection | indication | 301013004 | |
Bacterial urinary infection | indication | 312124009 | |
Gram-Negative Bacterial Infections | indication | 371583007 | |
Urinary tract infection caused by Klebsiella | indication |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 2.35 | acidic |
pKa2 | 3.44 | acidic |
pKa3 | 6.17 | acidic |
pKa4 | 9.6 | acidic |
pKa5 | 13.61 | acidic |
pKa6 | 2.83 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
EQ 1GM BASE/VIAL | FETROJA | SHIONOGI INC | N209445 | Nov. 14, 2019 | RX | POWDER | INTRAVENOUS | 9238657 | Nov. 14, 2033 | METHOD OF TREATING BACTERIAL INFECTIONS |
EQ 1GM BASE/VIAL | FETROJA | SHIONOGI INC | N209445 | Nov. 14, 2019 | RX | POWDER | INTRAVENOUS | 9238657 | Nov. 14, 2033 | METHOD OF TREATING COMPLICATED URINARY TRACT INFECTIONS (CUTI), INCLUDING PYELONEPHRITIS, COMPRISING ADMINISTERING CEFIDEROCOL SULFATE TOSYLATE |
EQ 1GM BASE/VIAL | FETROJA | SHIONOGI INC | N209445 | Nov. 14, 2019 | RX | POWDER | INTRAVENOUS | 9238657 | Nov. 14, 2033 | METHOD OF TREATING HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) COMPRISING ADMINISTERING CEFIDEROCOL SULFATE TOSYLATE |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
EQ 1GM BASE/VIAL | FETROJA | SHIONOGI INC | N209445 | Nov. 14, 2019 | RX | POWDER | INTRAVENOUS | Sept. 25, 2023 | INDICATED IN PATIENTS 18 YEARS OF AGE AND OLDER FOR THE TREATMENT OF HOSPITAL ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) CAUSED BY THE FOLLOWING SUSCEPTIBLE GRAM-NEGATIVE MICROORGANISMS: ACINETOBACTER BAUMANNII COMPLEX, ESCHERICHIA COLI, ENTEROBACTER CLOACAE COMPLEX, KLEBSIELLA PNEUMONIAE, PSEUDOMONAS AERUGINOSA, AND SERRATIA MARCESCENS |
EQ 1GM BASE/VIAL | FETROJA | SHIONOGI INC | N209445 | Nov. 14, 2019 | RX | POWDER | INTRAVENOUS | Nov. 14, 2024 | NEW CHEMICAL ENTITY |
EQ 1GM BASE/VIAL | FETROJA | SHIONOGI INC | N209445 | Nov. 14, 2019 | RX | POWDER | INTRAVENOUS | Nov. 14, 2029 | GENERATING ANTIBIOTIC INCENTIVES NOW |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Peptidoglycan synthase FtsI | Enzyme | INHIBITOR | IC50 | 7.40 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
Penicillin-binding protein 1A | Enzyme | INHIBITOR | IC50 | 6.07 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
Penicillin-binding protein 1A | Enzyme | INHIBITOR | IC50 | 5.48 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
Penicillin-binding protein 1B | Enzyme | INHIBITOR | IC50 | 5.47 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
Penicillin-binding protein 1A | Enzyme | INHIBITOR | IC50 | 5.98 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
Penicillin-binding protein 1B | Enzyme | INHIBITOR | IC50 | 5.46 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
Peptidoglycan D,D-transpeptidase MrdA | Enzyme | INHIBITOR | IC50 | 5.66 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
Peptidoglycan D,D-transpeptidase MrdA | Enzyme | INHIBITOR | IC50 | 7.20 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
Peptidoglycan D,D-transpeptidase FtsI | Enzyme | INHIBITOR | IC50 | 7.21 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
Peptidoglycan D,D-transpeptidase FtsI | Enzyme | INHIBITOR | IC50 | 7.22 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
Peptidoglycan D,D-transpeptidase FtsI | Enzyme | INHIBITOR | IC50 | 6.17 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
Penicillin-binding protein 4 | Enzyme | INHIBITOR | IC50 | 5.44 | SCIENTIFIC LITERATURE | DRUG LABEL |
ID | Source |
---|---|
SZ34OMG6E8 | UNII |
2135543-94-9 | SECONDARY_CAS_RN |
C4548369 | UMLSCUI |
CHEBI:140376 | CHEBI |
CHEMBL3989974 | ChEMBL_ID |
77843966 | PUBCHEM_CID |
DB14879 | DRUGBANK_ID |
CHEMBL4297211 | ChEMBL_ID |
D11302 | KEGG_DRUG |
10234 | INN_ID |
10776 | IUPHAR_LIGAND_ID |
018219 | NDDF |
018220 | NDDF |
1217151007 | SNOMEDCT_US |
830101009 | SNOMEDCT_US |
830161006 | SNOMEDCT_US |
4039174 | VANDF |
2265702 | RXNORM |
37832 | MMSL |
d09462 | MMSL |
C000612166 | MESH_SUPPLEMENTAL_RECORD_UI |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Fetroja | HUMAN PRESCRIPTION DRUG LABEL | 1 | 59630-266 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAVENOUS | NDA | 31 sections |